{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:10:01Z","timestamp":1792815001149,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bioorg.2024.107984","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T10:28:02Z","timestamp":1732271282000},"page":"107984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies"],"prefix":"10.1016","volume":"154","author":[{"given":"M","family":"Malarvannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1298-8194","authenticated-orcid":false,"given":"Sujith","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Monohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Ravichandiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-2123","authenticated-orcid":false,"given":"David","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107984_b0005","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2024.107984_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2024.107984_b0015","doi-asserted-by":"crossref","unstructured":"A. Mittal, R. Ghai, A. Srivastava, D.P. Ghosh, K. Nagarajan, Pharmacokinetics and Pharmacodynamics: Fundamentals and Role(s) in Drug Discovery and Development, in: P.P. Singh (Ed.) Recent Advances in Pharmaceutical Innovation and Research, (2023), 357-393. 10.1007\/978-981-99-2302-1_15.","DOI":"10.1007\/978-981-99-2302-1_15"},{"key":"10.1016\/j.bioorg.2024.107984_b0020","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bioorg.2024.107984_b0025","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. u.s.a."},{"key":"10.1016\/j.bioorg.2024.107984_b0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/med.1009","article-title":"The ubiquitin-proteasome pathway and proteasome inhibitors","volume":"21","author":"Myung","year":"2001","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2024.107984_b0035","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2024.107984_b0040","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: A safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107984_b0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00894-020-04385-6","article-title":"Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say?","volume":"26","author":"Agoni","year":"2020","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.bioorg.2024.107984_b0050","first-page":"228","article-title":"New approaches to targeting the androgen receptor pathway in prostate cancer","volume":"19","author":"Velho","year":"2021","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.107984_b0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1120","article-title":"ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+\/human epidermal growth factor receptor 2\u2013negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1\/2 study","volume":"40","author":"Hamilton","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.107984_b0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41422-019-0144-9","article-title":"Degrading proteins in animals: \u201cPROTAC\u201dtion goes in vivo","volume":"29","author":"Guo","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2024.107984_b0065","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2024.107984_b0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.107984_b0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/13543784.2017.1351941","article-title":"Do STAT3 inhibitors have potential in the future for cancer therapy?","volume":"26","author":"Wong","year":"2017","journal-title":"Expert Opin. Investig. Drugs ."},{"key":"10.1016\/j.bioorg.2024.107984_b0080","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1021\/acs.jmedchem.9b01393","article-title":"Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0090","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Amer. Chem. Soci."},{"key":"10.1016\/j.bioorg.2024.107984_b0095","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioorg.2024.107984_b0100","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bioorg.2024.107984_b0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC Technology: Opportunities and Challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett ."},{"key":"10.1016\/j.bioorg.2024.107984_b0110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41416-018-0355-8","article-title":"A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours","volume":"120","author":"de Weger","year":"2019","journal-title":"Brit. J. Cancer."},{"key":"10.1016\/j.bioorg.2024.107984_b0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A Practical Review of Proteasome Pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2024.107984_b0120","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2533\/chimia.2020.274","article-title":"Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology","volume":"74","author":"Cecchini","year":"2020","journal-title":"Chimia (aarau)"},{"key":"10.1016\/j.bioorg.2024.107984_b0130","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2024.107984_b0135","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: a large-scale bioactivity database for drug discovery","volume":"40","author":"Gaulton","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"2016","key":"10.1016\/j.bioorg.2024.107984_b0140","first-page":"D1045","article-title":"BindingDB in, A public database for medicinal chemistry, computational chemistry and systems pharmacology","volume":"44","author":"Gilson","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2024.107984_b0145","doi-asserted-by":"crossref","first-page":"D1367","DOI":"10.1093\/nar\/gkac946","article-title":"PROTAC-DB 2.0: an updated database of PROTACs","volume":"51","author":"Weng","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2024.107984_b0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"Irwin","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2024.107984_b0155","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bioorg.2024.107984_b0160","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1021\/acs.jcim.0c01451","article-title":"Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta","volume":"61","author":"Bai","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2024.107984_b0165","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1021\/acs.jcim.0c00589","article-title":"PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes","volume":"60","author":"Zaidman","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2024.107984_b0170","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1002\/cpz1.611","article-title":"Targeted Protein Degradation: Design Considerations for PROTAC Development","volume":"2","author":"Tran","year":"2022","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.bioorg.2024.107984_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104032","article-title":"The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation","volume":"29","author":"Sobierajski","year":"2024","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.bioorg.2024.107984_b0180","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0185","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0190","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.gpb.2022.11.008","article-title":"Machine Learning Modeling of Protein-intrinsic Features Predicts Tractability of Targeted Protein Degradation","volume":"20","author":"Zhang","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.bioorg.2024.107984_b0195","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2024.107984_b0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.107984_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. b."},{"key":"10.1016\/j.bioorg.2024.107984_b0210","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2024.107984_b0215","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107984_b0220","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0230","first-page":"1514","article-title":"Chemo-proteomics exploration of HDAC degradability by small molecule degraders, Cell","volume":"28","author":"Xiong","year":"2021","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0235","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma","volume":"28","author":"Tong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.107984_b0240","first-page":"194","article-title":"Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates","volume":"63","author":"Masungi","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.bioorg.2024.107984_b0245","first-page":"1182","article-title":"Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation, ACS Med","volume":"13","author":"Hendrick","year":"2022","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107984_b0250","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/acschembio.5b00753","article-title":"NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells","volume":"11","author":"Dixon","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0255","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin-proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2024.107984_b0260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107984_b0265","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2024.107984_b0270","first-page":"41","article-title":"EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex, Cell","volume":"27","author":"Hsu","year":"2020","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0275","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1039\/D1CB00069A","article-title":"Computational analyses of mechanism of action (MoA): data, methods and integration","volume":"3","author":"Trapotsi","year":"2022","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0280","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2024.107984_b0285","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0002-9440(10)64779-7","article-title":"Mechanisms of Apoptosis","volume":"157","author":"Reed","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2024.107984_b0290","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0295","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40259-022-00551-9","article-title":"PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras","volume":"36","author":"Madan","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.bioorg.2024.107984_b0300","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1021\/acs.jcim.4c01227","article-title":"Characterizing the Cooperative Effect of PROTAC Systems with End-Point Binding Free Energy Calculation","volume":"64","author":"Xu","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2024.107984_b0305","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2022.08.048","article-title":"Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation","volume":"628","author":"Gross","year":"2022","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.bioorg.2024.107984_b0310","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2174\/1389557521666210226150740","article-title":"PROTACs in Treatment of Cancer: A Review","volume":"21","author":"Arora","year":"2021","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0315","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1021\/acs.molpharmaceut.9b00673","article-title":"TrkC-Targeted Kinase Inhibitors And PROTACs","volume":"16","author":"Zhao","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2024.107984_b0320","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. b."},{"key":"10.1016\/j.bioorg.2024.107984_b0325","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1021\/acsmedchemlett.0c00235","article-title":"PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107984_b0330","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.neo.2020.07.002","article-title":"A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo","volume":"22","author":"Zhao","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.bioorg.2024.107984_b0335","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.107984_b0340","first-page":"47","article-title":"ARe we there yet?","volume":"6","author":"Michmerhuizen","year":"2020","journal-title":"Understanding Androgen Receptor Signaling in Breast Cancer, Npj Breast Cancer"},{"key":"10.1016\/j.bioorg.2024.107984_b0345","doi-asserted-by":"crossref","first-page":"17942","DOI":"10.1073\/pnas.1208396109","article-title":"Inhibition of oncogenic Wnt signaling through direct targeting of \u03b2-catenin","volume":"109","author":"Grossmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2024.107984_b0350","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1\u03b1 by pVHL","volume":"417","author":"Hon","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2024.107984_b0355","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1073\/pnas.1002713107","article-title":"Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic","volume":"107","author":"Bird","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2024.107984_b0360","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ymthe.2022.11.011","article-title":"PROTAC therapy as a new targeted therapy for lung cancer","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioorg.2024.107984_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112781","article-title":"Discovery of potent small molecule PROTACs targeting mutant EGFR","volume":"208","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2024.107984_b0375","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring Targeted Degradation Strategy for Oncogenic KRAS(G12C)","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0380","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0385","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1021\/acs.jmedchem.7b01655","article-title":"Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)","volume":"61","author":"Powell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0390","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.107984_b0395","article-title":"Chemotherapy-Enabled Colorectal Cancer Immunotherapy of Self-Delivery Nano-PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance","volume":"11","author":"Zhao","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioorg.2024.107984_b0400","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1021\/acs.jmedchem.0c00929","article-title":"Discovery of Novel PDE\u03b4 Degraders for the Treatment of KRAS Mutant Colorectal Cancer","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0405","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1021\/acs.jmedchem.4c00454","article-title":"Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0410","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41419-020-03015-6","article-title":"The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells","volume":"11","author":"Qin","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2024.107984_b0415","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cellimm.2019.02.001","article-title":"Emerging roles of and therapeutic strategies targeting BRD4 in cancer","volume":"337","author":"White","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bioorg.2024.107984_b0420","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","article-title":"The Bromodomain Protein Brd4 Is a Positive Regulatory Component of P-TEFb and Stimulates RNA Polymerase II-Dependent Transcription","volume":"19","author":"Jang","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2024.107984_b0425","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-15-0724","article-title":"Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells","volume":"15","author":"T\u00f6gel","year":"2016","journal-title":"Mol. Cancer. Ther."},{"key":"10.1016\/j.bioorg.2024.107984_b0430","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153778","article-title":"Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies","volume":"14","author":"Wolska-Washer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2024.107984_b0435","unstructured":"D.C. Moore, D. Thompson, A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies, J. Adv. Pract. Oncol. 12 (2021) 439-447. 10.6004%2Fjadpro.2021.12.4.8."},{"key":"10.1016\/j.bioorg.2024.107984_b0440","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J.hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.107984_b0445","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-141461","article-title":"Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies","volume":"136","author":"Robbins","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.107984_b0450","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2024.107984_b0455","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1039\/C9CC08238G","article-title":"Protein degradation through covalent inhibitor-based PROTACs","volume":"56","author":"Xue","year":"2020","journal-title":"Chem. Comm."},{"key":"10.1016\/j.bioorg.2024.107984_b0460","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2024.107984_b0465","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2012.01112.x","article-title":"Roles of BCL6 in normal and transformed germinal center B cells","volume":"247","author":"Basso","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bioorg.2024.107984_b0470","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41586-020-2925-1","article-title":"Small-molecule-induced polymerization triggers degradation of BCL6","volume":"588","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2024.107984_b0475","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.107984_b0480","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2024.107984_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2024.107984_b0490","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-022-02483-2","article-title":"Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107984_b0495","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107984_b0500","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0505","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s42004-024-01177-4","article-title":"Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader","volume":"7","author":"Carmona","year":"2024","journal-title":"Commun. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105162","article-title":"Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response","volume":"104","author":"Xu","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bioorg.2024.107984_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102137","article-title":"Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3","volume":"35","author":"Hall","year":"2024","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.bioorg.2024.107984_b0520","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41467-023-44237-4","article-title":"DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance","volume":"15","author":"Schr\u00f6der","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107984_b0525","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12885-024-12244-3","article-title":"PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis","volume":"24","author":"Shi","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2024.107984_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104994","article-title":"Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML)","volume":"299","author":"Zhang","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0535","author":"Velez","year":"2024","journal-title":"J. Jin, Discovery of the First-in-Class G9a\/GLP PROTAC Degrader, bioRxiv"},{"key":"10.1016\/j.bioorg.2024.107984_b0540","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s42003-024-06238-x","article-title":"Metabolism-driven in vitro\/in vivo disconnect of an oral ER\u0251 VHL-PROTAC","volume":"7","author":"Hayhow","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0545","doi-asserted-by":"crossref","unstructured":"X. Zhang, S. Li, M. Song, Y. Chen, L. Chang, Z. Liu, H. Dai, Y. Wang, G. Yang, Y. Jiang, Y. Lu, Degradation of FAK-targeting by proteolytic targeting chimera technology to inhibit the metastasis of hepatocellular carcinoma, Oncol. Res. 32 (2024) 679-690. 10.32604%2For.2024.046231.","DOI":"10.32604\/or.2024.046231"},{"key":"10.1016\/j.bioorg.2024.107984_b0550","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1196005","article-title":"BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival","volume":"13","author":"Champion","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2024.107984_b0555","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1039\/C9CC08391J","article-title":"Degradation of intracellular TGF-\u03b21 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events","volume":"56","author":"Feng","year":"2020","journal-title":"Chem. Commun (camb)"},{"key":"10.1016\/j.bioorg.2024.107984_b0560","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.chembiol.2022.10.007","article-title":"Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation","volume":"29","author":"Zhu","year":"2022","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112451","article-title":"Optimal linker length for small molecule PROTACs that selectively target p38\u03b1 and p38\u03b2 for degradation","volume":"201","author":"Donoghue","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0570","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.jmedchem.9b00810","article-title":"Design, Synthesis, and Biological Evaluation of MEK PROTACs","volume":"63","author":"Vollmer","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0575","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104833","article-title":"In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)","volume":"111","author":"Wang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0590","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta. Pharm. Sin. b."},{"key":"10.1016\/j.bioorg.2024.107984_b0595","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1021\/acsmedchemlett.0c00046","article-title":"Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase","volume":"11","author":"Yang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107984_b0600","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)","volume":"61","author":"Schiedel","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0605","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41589-020-0609-7","article-title":"Functional characterization of a PROTAC directed against BRAF mutant V600E","volume":"16","author":"Posternak","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0610","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0615","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2024.107984_b0620","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0962-8924(94)90069-8","article-title":"Autophagy and related mechanisms of lysosome-mediated protein degradation","volume":"4","author":"Dunn","year":"1994","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bioorg.2024.107984_b0625","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/acsmedchemlett.2c00479","article-title":"Development of Oligomeric Mannose-6-phosphonate Conjugates for Targeted Protein Degradation","volume":"14","author":"Stevens","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107984_b0630","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0635","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","article-title":"Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins","volume":"41","author":"Pance","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bioorg.2024.107984_b0640","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1089\/ars.2013.5371","article-title":"An overview of autophagy: morphology, mechanism, and regulation","volume":"20","author":"Parzych","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.bioorg.2024.107984_b0645","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41422-021-00532-7","article-title":"Degradation of lipid droplets by chimeric autophagy-tethering compounds","volume":"31","author":"Fu","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.bioorg.2024.107984_b0650","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41576-022-00562-w","article-title":"Autophagy genes in biology and disease","volume":"24","author":"Yamamoto","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bioorg.2024.107984_b0655","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2024.107984_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116688","article-title":"Autophagy modulation in cancer therapy: Challenges coexist with opportunities","volume":"276","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107984_b0665","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance Mutation in Bruton\u2019s Tyrosine Kinase Using PROTAC-Mediated Degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T21:01:47Z","timestamp":1736456507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824008897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":133,"alternative-id":["S0045206824008897"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107984","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107984"}}